CYP Inhibition-Mediated Drug-Drug Interactions

E-ISSN： 1875-6662|6|3|130-145

ISSN： 1573-4080

Source： Current Enzyme Inhibition, Vol.6, Iss.3, 2010-10, pp. : 130-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data

By Rioux Nathalie Batonga Joëlle Colombo Federico Massé Jonathan Zouki Christine Ribadeneira Maria D. Duan Jianmin Bethell Richard C.

Xenobiotica, Vol. 43, Iss. 7, 2013-07 ,pp. : 592-597

Informa Healthcare

Access to resources Recommend Favorite

Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

By Tachibana T. Kato M. Watanabe T. Mitsui T. Sugiyama Y.

Xenobiotica, Vol. 39, Iss. 6, 2009-06 ,pp. : 430-443

Informa Healthcare

Access to resources Recommend Favorite

Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans

By Kanazu T. Yamaguchi Y. Okamura N. Baba T. Koike M.

Xenobiotica, Vol. 34, Iss. 5, 2004-05 ,pp. : 391-402

Informa Healthcare

Access to resources Recommend Favorite

Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats

By Kanazu T. Yamaguchi Y. Okamura N. Baba T. Koike M.

Xenobiotica, Vol. 34, Iss. 5, 2004-05 ,pp. : 403-413

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of cytochrome P450-mediated drug–drug interactions based on the strategies recommended by regulatory authorities

By Kosugi Yohei Hirabayashi Hideki Igari Tomoko Fujioka Yasushi Hara Yoko Okuda Teruaki Moriwaki Toshiya

Xenobiotica, Vol. 42, Iss. 2, 2012-02 ,pp. : 127-138

Informa Healthcare

Access to resources Recommend Favorite